Pleural Diseases and Chest Imaging

The pleural space is a potential cavity between the visceral and parietal pleura, normally containing 5-15 mL of pleural fluid. This thin layer of fluid serves as a lubricant, allowing smooth movement during respiration while maintaining surface tension that keeps the lungs expanded against the chest wall.

The parietal pleura lines the chest wall, diaphragm, and mediastinum, while the visceral pleura covers the lung surface. The pleural space maintains a negative pressure of -5 to -10 cmH₂O during quiet respiration, which is essential for lung expansion.

Pleural fluid formation occurs primarily through filtration from parietal pleural capillaries, following Starling's law. Normal pleural fluid has low protein content (<3 g/dL), low lactate dehydrogenase (LDH), and few cells (<1,000 cells/μL, predominantly mesothelial cells and macrophages). The lymphatic system, particularly through parietal pleural stomata, provides the primary drainage mechanism.

Disruption of this delicate balance leads to pleural diseases. Increased fluid production, decreased drainage, or air entry into the pleural space results in pleural effusion or pneumothorax, respectively. Understanding these normal mechanics is crucial for interpreting pathological conditions.

Key anatomical landmarks for chest imaging:

• Costophrenic angles: Sharp, acute angles where diaphragm meets chest wall
• Cardiophrenic angles: Angles between heart border and diaphragm
• Horizontal fissure: Separates right upper and middle lobes
• Oblique fissures: Separate upper from lower lobes bilaterally

The pleural space extends from the lung apex to the costophrenic sulci, with the posterior sulcus extending to approximately the T12 vertebral level. This anatomy explains why small effusions are first visible in the posterior costophrenic angles on lateral chest radiographs.

Pleural effusion occurs when fluid accumulates in the pleural space due to imbalanced fluid formation and absorption. The primary classification divides effusions into transudates and exudates based on Light's criteria, which has diagnostic and therapeutic implications.

Transudate formation mechanisms:

• Increased hydrostatic pressure (heart failure, fluid overload)
• Decreased oncotic pressure (hypoalbuminemia, nephrotic syndrome)
• Increased negative pleural pressure (atelectasis)

Transudates typically result from systemic causes and have low protein and LDH levels. Common causes include congestive heart failure (most common), cirrhosis with ascites, nephrotic syndrome, and myxedema.

Exudate formation mechanisms:

• Increased capillary permeability (inflammation, infection)
• Impaired lymphatic drainage (malignancy, radiation)
• Pleural surface injury (trauma, infection)

Exudates indicate local pleural disease with high protein and LDH levels. Major causes include:

• Malignant effusions (lung cancer, breast cancer, lymphoma): Most common cause of exudative effusion
• Parapneumonic effusions: Associated with pneumonia
• Empyema: Frank pus in pleural space
• Tuberculosis: Chronic granulomatous inflammation
• Pulmonary embolism: Inflammatory response
• Rheumatologic diseases: RA, SLE, drug-induced

Light's Criteria for Exudate (any one criterion):

1. Pleural fluid protein/serum protein ratio >0.5
2. Pleural fluid LDH/serum LDH ratio >0.6
3. Pleural fluid LDH >2/3 upper limit of normal serum LDH

Sensitivity approaches 98% for identifying exudates, though specificity is lower (83%). Additional tests may include glucose, pH, cell count with differential, cytology, and microbiological studies based on clinical suspicion.

Pneumothorax is the presence of air in the pleural space, disrupting the negative pressure essential for lung expansion. Classification is based on underlying lung pathology and mechanism of air entry.

Primary Spontaneous Pneumothorax (PSP): Occurs in healthy individuals without underlying lung disease. Most common in tall, thin young males (male:female ratio 6:1), with peak incidence between ages 20-30 years. The pathogenesis involves rupture of subpleural blebs or bullae, often located in the lung apices. Risk factors include smoking (increases risk 20-fold), Marfan syndrome, and atmospheric pressure changes.

Secondary Spontaneous Pneumothorax (SSP): Occurs in patients with underlying lung disease, carrying higher morbidity and mortality. Common causes include:

• COPD: Most common cause of SSP
• Asthma: Especially poorly controlled
• Interstitial lung diseases: Pulmonary fibrosis, sarcoidosis
• Infectious diseases: Pneumocystis pneumonia, tuberculosis
• Cystic fibrosis: Progressive lung destruction
• Malignancy: Primary or metastatic lung cancer

Traumatic Pneumothorax:

• Penetrating trauma: Direct pleural injury
• Blunt trauma: Rib fractures, sudden pressure changes
• Iatrogenic: Central line placement, thoracentesis, mechanical ventilation, lung biopsy

Tension Pneumothorax: Life-threatening condition where air enters pleural space but cannot escape, creating a one-way valve mechanism. Progressive air accumulation increases intrapleural pressure, causing:

• Mediastinal shift away from affected side
• Compression of contralateral lung
• Decreased venous return and cardiac output
• Hemodynamic compromise

Pathophysiology: Pneumothorax disrupts the pressure gradient maintaining lung expansion. As air accumulates, lung elastic recoil causes progressive collapse. Small pneumothoraces (<20% lung volume) may be asymptomatic, while larger ones cause dyspnea and chest pain. The degree of physiologic impairment depends on pneumothorax size, underlying lung function, and patient age.

Systematic chest X-ray interpretation requires a structured approach to identify pleural diseases accurately. The standard approach involves assessing technical factors, followed by systematic review of anatomical structures.

Technical Assessment:

• Projection: PA (preferred) vs. AP (portable)
• Inspiration: Adequate if 8-10 posterior ribs visible
• Rotation: Medial clavicular heads equidistant from vertebral spinous processes
• Penetration: Vertebral bodies just visible through cardiac shadow

Systematic Review Sequence:

1. Airways and Mediastinum:

• Tracheal position and caliber
• Mediastinal contours and width
• Hilar size and symmetry

2. Cardiac Silhouette:

• Size (cardiothoracic ratio <50% on PA film)
• Shape and borders
• Position

3. Lung Fields:

• Compare symmetry between sides
• Assess for masses, consolidation, or infiltrates
• Evaluate lung volumes

4. Pleural Spaces:

• Costophrenic angles: Should be sharp and clear
• Pleural lines: Visceral pleural edge in pneumothorax
• Hemidiaphragm contours: Smooth, dome-shaped

5. Bones and Soft Tissues:

• Rib integrity and alignment
• Clavicles and shoulder girdle
• Soft tissue emphysema

Pleural Effusion Radiographic Signs:

• Small effusions (>75 mL): Blunting of posterior costophrenic angle on lateral view
• Moderate effusions (>175 mL): Blunting of lateral costophrenic angle on PA view
• Large effusions: Homogeneous opacity with concave upper border (meniscus sign)
• Massive effusions: Complete opacification of hemithorax with mediastinal shift

Pneumothorax Radiographic Signs:

• Visible pleural line: Thin white line representing visceral pleura
• Absent lung markings: Beyond the pleural line
• Deep sulcus sign: On supine films, unusually deep lateral costophrenic sulcus
• Mediastinal shift: Away from pneumothorax in tension pneumothorax

Pleural Effusion Diagnostic Algorithm

Pleural Effusion Suspected ↓ Chest X-ray/CT ↓ Thoracentesis ↓ Apply Light's Criteria ↓ ┌─────────────┐ │ TRANSUDATE │ └─────────────┘ ↓ • CHF (most common) • Cirrhosis • Nephrotic syndrome • Hypothyroidism ↓ Treat underlying condition

       ↓
┌─────────────┐
│   EXUDATE    │
└─────────────┘
       ↓

Further pleural fluid analysis: • Cytology (malignancy) • Culture (infection) • Glucose, pH (empyema) • ADA (tuberculosis) • Triglycerides (chylothorax) ↓ Specific treatment based on etiology

Pneumothorax Management Algorithm

Pneumothorax Suspected ↓ Chest X-ray ↓ ┌─────────────────┐ │ TENSION FEATURES?│ │ • Hemodynamic │ │ instability │ │ • Mediastinal │ │ shift │ └─────────────────┘ ↓ YES │ NO ↓ ↓ Immediate Size Assessment needle ↓ decompression ┌─────────┐ ↓ │ PRIMARY │ Tube │ PSP │ thoracostomy └─────────┘ ↓ <50% and >50% or asymptomatic symptomatic ↓ ↓ Observation Aspiration + O₂ or chest tube ↓ ↓ F/u CXR Tube removal in 24h when expanded + no air leak

              ┌─────────┐
              │SECONDARY│
              │ SSP     │
              └─────────┘
                   ↓
              Any size →
              Hospital admission
                   ↓
              >50% or    <50% and
              symptomatic stable
                   ↓         ↓
              Chest tube  Aspiration
                   ↓         ↓
              Consider    Monitor
              surgery if   closely
              recurrent

Key Decision Points:

Thoracentesis Indications:

• New pleural effusion >10 mm on lateral decubitus view
• Atypical presentation for CHF
• Fever or chest pain
• Asymmetric bilateral effusions

Contraindications (relative):

• Bleeding diathesis (INR >2.0, platelets <50,000)
• Mechanical ventilation
• Small effusion (<10 mm)

Pneumothorax Size Calculation: Using the Light's formula: % collapse = 100 × [1 - (DL/DH)³] Where DL = diameter of collapsed lung, DH = diameter of hemithorax

Advanced imaging modalities provide enhanced diagnostic capability and guide therapeutic interventions for complex pleural diseases.

Computed Tomography (CT): CT offers superior sensitivity for detecting small pleural effusions and pneumothoraces, particularly in critically ill patients on mechanical ventilation. High-resolution CT (HRCT) can detect effusions as small as 5-10 mL compared to 175 mL on chest X-ray.

CT advantages:

• Distinguishes pleural fluid from pleural thickening
• Identifies loculated effusions
• Detects underlying lung parenchymal disease
• Guides drainage procedures
• Evaluates for malignant pleural involvement

Pleural enhancement patterns on contrast CT:

• Smooth enhancement: Suggests benign etiology (CHF, infection)
• Nodular enhancement: Highly suggestive of malignancy
• Circumferential enhancement >1 cm: Concerning for malignancy

Ultrasound: Point-of-care ultrasonography has revolutionized pleural procedures with real-time guidance and improved safety profiles.

Ultrasound findings:

• Pleural effusion: Anechoic or hypoechoic fluid collection
• Complex effusions: Septations, echogenic debris (suggests empyema/hemorrhage)
• Pneumothorax: Absence of lung sliding, lung point sign

Procedural guidance benefits:

• Reduced complications (pneumothorax rate <1% vs. 15% blind)
• Improved success rates
• Real-time needle/catheter visualization
• Identification of safe entry sites

Interventional Procedures:

Thoracentesis: Diagnostic and therapeutic removal of pleural fluid using ultrasound guidance.

Technique:

1. Patient positioning: Sitting upright, leaning forward
2. Site selection: Posterior axillary line, 1-2 intercostal spaces below fluid level
3. Local anesthesia: Lidocaine infiltration
4. Needle insertion: Over rib superior border to avoid neurovascular bundle
5. Fluid removal: Maximum 1.5 L in single session

Chest Tube Thoracostomy: Indicated for large pneumothoraces, empyema, hemothorax, or recurrent effusions.

Insertion technique:

1. Site: 4th-5th intercostal space, anterior axillary line
2. Blunt dissection through chest wall
3. Digital exploration of pleural space
4. Tube advancement toward apex (pneumothorax) or base (effusion)
5. Connection to underwater seal drainage system

Tube removal criteria:

• <150 mL output per day for effusion
• No air leak for 24 hours (pneumothorax)
• Lung fully expanded on chest X-ray

Video-Assisted Thoracoscopic Surgery (VATS): Minimally invasive surgical approach for:

• Persistent air leaks
• Recurrent pneumothorax
• Empyema with thick septations
• Pleural biopsy for diagnosis
• Pleurodesis for malignant effusions

Management of pleural diseases requires individualized approaches based on etiology, patient factors, and disease severity. Understanding potential complications is crucial for optimal outcomes.

Pleural Effusion Management:

Transudative Effusions: Primarily treat underlying condition:

• CHF: Diuretics, ACE inhibitors, salt restriction
• Cirrhosis: Diuretics, paracentesis if tense ascites
• Nephrotic syndrome: Protein replacement, immunosuppression

Therapeutic thoracentesis may provide symptomatic relief but effusion typically recurs without addressing underlying cause.

Malignant Effusions: Poor prognosis with median survival 3-12 months depending on primary tumor.

Management options:

• Recurrent thoracentesis: For patients with limited life expectancy
• Pleurodesis: Chemical (talc) or mechanical scarring to prevent reaccumulation
• Indwelling pleural catheter: Allows outpatient drainage
• Systemic therapy: Chemotherapy for chemosensitive tumors

Parapneumonic Effusions and Empyema: Classified using Light's criteria for infection:

• Category 1: Small effusion, pH >7.30, glucose >60 mg/dL
• Category 2: Large effusion, pH 7.00-7.30, glucose 40-60 mg/dL
• Category 3: Frank pus, pH <7.00, glucose <40 mg/dL

Treatment approach:

• Category 1: Antibiotics alone
• Category 2: Antibiotics + drainage consideration
• Category 3: Antibiotics + drainage mandatory

Pneumothorax Management:

Conservative Management: Appropriate for small (<20%), asymptomatic primary pneumothoraces. Air reabsorbs at rate of 1.25% per day (faster with supplemental oxygen).

Monitoring requirements:

• Serial chest X-rays
• Symptom assessment
• Patient education on when to seek care

Interventional Management: Needle aspiration: First-line for primary pneumothorax >20% or symptomatic Chest tube drainage: Secondary pneumothorax, failed aspiration, tension pneumothorax

Recurrence Prevention:

• Smoking cessation: Reduces recurrence risk
• Surgical intervention: VATS bullectomy + pleurodesis for recurrent pneumothorax
• Activity modification: Avoid activities with rapid pressure changes

Complications:

Procedural Complications:

• Pneumothorax (thoracentesis): 5-15% incidence
• Bleeding: Risk factors include anticoagulation, thrombocytopenia
• Infection: Empyema from contaminated procedure
• Re-expansion pulmonary edema: Rapid lung expansion after large volume drainage

Disease-specific Complications:

• Trapped lung: Inability to expand due to pleural peel
• Bronchopleural fistula: Persistent air leak >7 days
• Fibrothorax: Extensive pleural scarring limiting expansion

Prevention strategies:

• Ultrasound guidance for all procedures
• Limit drainage volume <1.5 L per session
• Appropriate antibiotic prophylaxis
• Early intervention for complex effusions